Endometrial cancer is the most prevalent gynecological malignancy in high-income countries, and the discovery of new biomarkers may aid in earlier detection and improve the prognosis of patients.

Significant sociodemographic disparities and unfavorable trends continue to affect the incidence and mortality of all 6 major female-specific cancers (FSCs), according to a study published in PLoS One ...

For many young adults, their late 20s are a time to dream about careers, families, and the future. But for Casey, those years were defined by something very different: a fight for her life. At 28, she ...

Sponsored by GSK. Sherry is a patient with endometrial cancer who will be discussing her experience; individual experiences may vary. Sherry has been compensated by GSK for her participation in this ...

ALBUQUERQUE, N.M. — A professor at the University of New Mexico Comprehensive Cancer Center has been awarded a 5-year, $12.9 million grant to study endometrial cancer. Dr. Kimberly Leslie is set to ...

It was quite a red flag. Alla Feldbeyn was stunned by unexpected vaginal bleeding in November 2020, many years after she had gone through menopause. The Florida grandmother of four was diagnosed with ...

Side effects depend on treatment type, and it’s important to tell your healthcare provider if you notice any. “Patients should be familiar with what signs and symptoms to monitor ‌and feel encouraged ...

Two molecular targets-human epidermal growth factor 2 (HER2) and cluster of differentiation 24 (CD24)-are highly promising candidates for new nuclear diagnostics and therapeutics for endometrial ...

Trastuzumab pamirtecan met its primary endpoint of progression-free survival in the phase 3 DYNASTY-Breast01 study for HER2-positive breast cancer. The study compared trastuzumab pamirtecan to ...

While anticancer treatments, including many forms of chemotherapy and radiation, can effectively kill cancer cells, long-term use can cause mutations in healthy cells. Mutations arising in cells that ...

Rina-S has received FDA breakthrough therapy designation for advanced endometrial cancer after standard treatments fail, based on promising Phase 1/2 trial results. The RAINFOL-01 trial showed ...

Findings showed in the rinatabart sesutecan 100mg/m 2 cohort, the confirmed ORR was 50%, with 2 patients achieving complete response. The Food and Drug Administration (FDA) has granted Breakthrough ...